retatrutide phase 2 trial type 2 diabetes weight loss 2024 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 Lilly's triple agonist, retatrutide, successful

Eli Lillys Phase 3 TRIUMPH-4 trial (December 2025) reported that participants taking 12mg of Retatrutide over 68 weeks lost an average of 28.7% of their body weight, the highest result ever reported at that stage for any obesity-related compound

Grns works with Plus Capital, which invests in companies on behalf of its celebrity partners

Personal, not medical advice

Women experience distinct hormonal transitions throughout their lives including puberty, pregnancy, and the menopause each of which can significantly influence body weight, fat distribution, and metabolic function

When your brain processes a competing tactile stimulus (toe wiggling), it dedicates fewer processing resources to the injection sensation

Retatrutide vs Tirzepatide